| Programme |
| Sunday 28 March 2010 | ||
| 14.00 – 17.00 | Workshop Medical Oncology | |
| Chairs: C.J.A. Punt, The Netherlands & C. Aschele, Italy | ||
| 14.00 | First-line treatment options for patients with KRAS wildtype tumors: is there a preference? | |
| C.J.A. Punt, The Netherlands | ||
| 14.25 | Toxicity as a surrogate endpoint for anti-VEGF and anti-EGFR treatment | |
| S. Cascinu, Italy | ||
| 14.50 | Vascular effects of anti-VEGF cancer therapy: insights from imaging | |
| t.b.a. | ||
| 15.15 – 15.45 | Break | |
| 15.45 | Factors associated with resistance to anti-EGFR and anti-VEGF therapy | |
| S. Siena, Italy | ||
| 16.10 | Chemotherapy partners for targeted therapy | |
| C. Aschele, Italy | ||
| 16.35 | Presentations of cases, Q&A | |
| 14.00 – 17.05 | Workshop Pathology | |
| Chairs: I.D. Nagtegaal, The Netherlands & J-F. Fléjou, France | ||
| 14.00 | Introduction | |
| DOWNLOAD | 14.15 | Lymph nodes: a pan-european viewpoint |
| Ph. Quirke, UK, C. Wittekind, Germany | ||
| 14.45 | TNM and lymph nodes | |
| C. Wittekind, Germany | ||
| 15.15 – 15.45 | Break | |
| 15.45 | Methylene blue assisted lymph node dissection ensures an adequate lymph node harvest in neoadjuvantly treated colorectal cancer | |
| B. Märkl, Germany | ||
| 16.05 | Variation in lymph node evaluation in rectal cancer, a nationwide population-based study in the Netherlands | |
| M. Elferink, The Netherlands | ||
| 16.25 | Improving lymph node detection in colon cancer in community hospitals and their pathology department in southern Netherlands | |
| L. van Steenbergen, The Netherlands | ||
| 16.45 | Discussion | |
| 14.00 – 17.30 | Workshop: How to recognize hereditary colorectal cancer? | |
|
Chairs: N. Hoogerbrugge, The Netherlands, Th. Friebourg, France, M. Genuardi, Italy |
||
| DOWNLOAD | Which patients with colorectal cancer (CRC) are at high risk for hereditary CRC? | |
| Case report: a CRC patient with a mutation in a mismatch repair gene, causing Lynch syndrome; what are the consequences for this patient and for family members? | ||
| 15.15 – 15.45 | Break | |
| Case report: CRC patient with a likely hereditary condition, but with no germline mutation detected upon genetic testing; what are the consequences for this patient and for family members? | ||
| Case report: CRC patient with a likely hereditary condition, who has an unclassified variation in a mismatch repair gene; what are the consequences for this patient and for his family members? | ||
| 14.00 – 17.00 | Workshop (MR) Imaging of rectal cancer | |
|
Chair: R.G.H. Beets-Tan, The Netherlands |
||
| 14.00 | Introduction | |
| R.G.H. Beets-Tan, The Netherlands | ||
| 14.05 | MR imaging, made easy | |
| J.Verwoerd, D. Lambregts, The Netherlands | ||
| 14.50 | What the surgeon needs to know | |
| G.L. Beets, The Netherlands | ||
| 15.20 – 15.50 | Break | |
| 15.50 | What the radiation-oncologist needs to know | |
| V. Valentini, Italy | ||
| 16.20 | MR Imaging in rectal cancer | |
| R.G.H. Beets-Tan, The Netherlands | ||
| 16.50 | Discussion | |
| 14.00 – 17.00 | Workshop: Radiotherapy and rectal cancer: an interactive workshop | |
| Chairs: C.A.M. Marijnen, The Netherlands & J.P. Gérard, France | ||
| 14.00 | Opening | |
| J.P. Gérard, France & C.A.M. Marijnen, The Netherlands | ||
| 14.05 |
Experience with cone beam -interfraction motion -intra fraction organ motion -what margins to use |
|
| J. Nijkamp, The Netherlands | ||
| 14.25 | TNM staging and tumour regression | |
| G. Brown, UK | ||
| 14.45 | Results of the ACCORD trial | |
| J.P. Gérard, France | ||
| 14.55 | Surgery for extramesorectal lymphnodes | |
| J. Baulieux, France | ||
| 15.05 | Location local recurrences | |
| C. Marijnen, The Netherlands | ||
| 15.15 – 15.30 | Break | |
| 15.30 | Delineation consensus | |
| C.A.M. Marijnen, The Netherlands & J. Nijkamp, The Netherlands | ||
| 15.45 |
Case Discussion: -target volume -extramesorectal lymphnodes -regression -wait and see |
|
| 14.00 – 17.00 | Workshop: Autonomic nerve function preservation & rectal cancer surgery | |
| Chair: K. Havenga, The Netherlands | ||
| 14.00 | Introduction | |
| K. Havenga, The Netherlands | ||
| DOWNLOAD | 14.15 | Sex and Rectal Cancer |
| S.O. Breukink, The Netherlands | ||
| 14.45 |
Late urogenital dysfunction Results from the Dutch TME trial |
|
| C.J.H. van de Velde, The Netherlands | ||
| 15.05 | Seven Times at Risk | |
| Th. Wiggers, The Netherlands | ||
| 15.35 – 15.50 | Break | |
| 15.50 | Preservation of sexual function and wide perineal resection | |
| T. Holm, Sweden | ||
| 16.10 | Preservation of sexual function and intersphincteric resection | |
| L. Temple, USA | ||
| 16.30 | Preservation of sexual function: Influence of radiation and surgical heat | |
| H. Becker, Germany | ||
| 16.50 | Discussion | |
| 17.45 – 18.00 | Opening ceremony | |
| 18.00 – 18.45 | Keynote lecture | |
| Chairs: J.P. Gérard, France & C.J.A. Punt, The Netherlands | ||
| 01.01 | Colorectal cancers - variations across Europe in incidence and survival | |
| J. Faivre, France | ||
| 18.45 – 19.30 | Welcome reception | |
| Monday 29 March 2010 | ||
| 08.30 – 18.00 |
How to read MRI of rectal cancer Interactive workshop on a computer |
|
| 08.30 - 09.45 | Prevention & screening | |
| Chairs: G.L. Beets, The Netherlands & C. Wittekind, Germany | ||
| 02.01 | 08.30 | Flat adenomas – morphological and molecular features? |
| M. Vieth, Germany | ||
| 02.02 | 08.50 | The importance of flat adenoma’s: should we really detect them? |
| A. Laghi, Italy | ||
| 02.03 | 09.10 | Colorectal cancer screening in Europe |
| DOWNLOAD | E. Kuipers, The Netherlands | |
| 02.04 | 09.30 | Stage distribution of Interval cancers in a population-based FOBT colorectal screening programme |
| R.J.C. Steele, UK | ||
| 09.45 - 11.05 | Update and comments on randomized CRC trials | |
| Chairs: J.P. Gérard, France & C.J.A. Punt, The Netherlands | ||
| 03.01 | 09.45 | Rectal cancer MRC trial |
| DOWNLOAD | D. Sebag- Montefiore, UK | |
| 03.02 | 09.55 | STAR trial |
| C. Aschele, Italy | ||
| 03.03 | 10.05 | DCCG CAIRO |
| M. Koopman, The Netherlands | ||
| 03.04 | 10.15 | Chronicle / SCRIPT/ PROCTOR trials |
| C.J.H. van de Velde, The Netherlands | ||
| 03.05 | 10.25 | ACCORD 12 Trial |
| DOWNLOAD | J.P. Gérard, France | |
| 03.06 | 10.35 | The TME trial after a median follow-up of 10 years |
| W. van Gijn The Netherlands | ||
| 03.07 | 10.45 | PRIME study: a randomised phase 3 study of panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment for metastatic colorectal cancer (mCRC) |
| S. Siena, Italy | ||
| 03.08 | 10.55 | Panitumumab with FOLFIRI vs FOLFIRI alone: a randomised phase 3 study for the second line treatment of patients (pts) with metastatic colorectal cancer (mCRC) |
| T. André, France | ||
| 11.05 - 11.30 | Break | |
| 11.30 - 12.45 | Diagnosis and follow-up | |
| Chairs: I.D. Nagtegaal, The Netherlands & R.G.H. Beets-Tan, The Netherlands | ||
| 04.01 | 11.30 | New perspectives of TNM (R-classification) |
| C. Wittekind, Germany | ||
| 04.02 | 11.50 | Colon cancer staging, new perspectives in whole body staging |
| DOWNLOAD | H. Kühl, Germany | |
| 04.03 | 12.10 | Follow Up after CRC treatment: what is the best tool? |
| L. Påhlman, Sweden | ||
| 04.04 | 12.30 | Development and validation of a robust high throughput gene expression test (ColoPrint) for risk stratification of colon cancer patients |
| S. Bruin, The Netherlands | ||
| 12.45 - 14.15 | Lunch | |
| 13.15 - 14.15 |
Satellite Symposium 2 organised by Merck Serono Personalising treatment: A new standard prolonging overall survival in mCRC |
|
| Chair: M. Ducreux, France | ||
| 13.15 | Introduction | |
| M. Ducreux, France | ||
| 13.20 | A selective approach to 1st-line treatment of mCRC | |
| E. Van Cutsem, Belgium | ||
| 13.40 | A multidisciplinary approach in mCRC treatment | |
| R. Adam, France | ||
| 14.00 | Case study: Panel discussion | |
| all | ||
| 14.10 | Summary | |
| M. Ducreux, France | ||
| 14.15 - 15.15 | Controversy session 1 | |
| Chairs: V. Valentini, Italy & E. Rullier, France | ||
| 05.01 | 14.15 | Partial mesorectal excision is sufficient for rectal cancer |
|
Pro:
H. Becker, Germany Contra: B. Heald, UK |
||
| 05.02 | 14.45 | Chemoradiation is always necessary in APR- resection |
|
Pro:
Radiotherapy: C.A.M. Marijnen,
The Netherlands Contra: Surgery: T. Holm, Sweden |
||
| 15.15 - 16.30 | Translational research 1 | |
| Chairs: J.P. Medema, The Netherlands & Ph. Quirke, UK | ||
| 06.01 | 15.15 | Prediction of tumour response beyond RAS |
| DOWNLOAD | S.Tejpar, Belgium | |
| 06.02 | 15.45 | Circulating tumour cells |
| K. Pantel, Germany | ||
| 06.03 | 16.15 | Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer |
| M.F. Frattini, Switzerland | ||
| 16.30 - 17.00 | Break | |
| 17.00 - 18.15 | Multidisciplinary management 1 | |
| Chairs: C.J.H. van de Velde, The Netherlands & F. Calvo, Spain | ||
| 07.01 | 17.00 | Rectal carcinoma. Intersphincteric resection: oncologic outcome and QoL |
| E. Tiret, France | ||
| 07.02 | 17.30 | Role of radioembolization of colorectal liver metastases |
| E. Cortesi, Italy | ||
| 07.03 | 18.00 | Results of European pooled analysis of IORT containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastases |
| M. Kusters, The Netherlands | ||
| 18.15 – 19.15 | Drinks and poster viewing | |
| 19.45 | Congress dinner / party at the Villa Ephrussi de Rothschild | |
| Tuesday 30 March 2010 | ||
| 08.30 – 18.00 |
How to read MRI of rectal cancer Interactive workshop on a computer |
|
| 08.30 - 09.45 | Genetics | |
| Chairs: N. Hoogerbrugge,The Netherlands & S. Siena, Italy | ||
| 08.01 | 08.30 | Chemoprevention of hereditary colorectal cancer |
| J. Burn, UK | ||
| 08.02 | 09.00 | What a medical/surgical oncologist should know of colorectal hereditary syndromes |
| S. Bülow, Denmark | ||
| 08.03 | 09.30 | The prognostic value of genetic variations in the vascular endothelial growth factor A gene in colorectal cancer |
| T.F.H. Hansen, Denmark | ||
| 09.45 - 11.00 | Evaluation of treatment | |
| Chairs: P. Flamen, Belgium & J.W. Leer, The Netherlands | ||
| 09.01 | 09.45 | PET-CT in diagnosis and follow-up |
| W. Weber, Germany | ||
| 09.02 | 10.05 | New evaluation tools for neoadjuvant treatment of rectal cancer - pathology |
| I.D. Nagtegaal, The Netherlands | ||
| 09.03 | 10.25 | New evaluation tools for neoadjuvant treatment of rectal cancer – imaging |
| R.G.H. Beets-Tan, The Netherlands | ||
| 09.04 | 10.45 | Prediction of response to chemoradiation of rectal cancer by consecutive endoscopies with biopsy |
| J. Pløen, Denmark | ||
| 11.00 - 11.30 | Break | |
| 11.30 - 12.45 | Translational research 2 | |
| Chairs: A. Cats, The Netherlands & S. Tejpar, Belgium | ||
| 10.01 | 11.30 | Colorectal stem cells |
| J.P. Medema, The Netherlands | ||
| 10.02 | 12.00 | Tumour microenvironment |
| DOWNLOAD | J. Huot (Canada) | |
| 10.03 | 12.30 | B-raf V600E mutation is a prognostic factor in stage II and III colon carcinoma patients |
| A. Fariña, The Netherlands | ||
| 12.45 - 14.00 | Lunch | |
| 13.00 - 14.00 |
Satellite Symposium 3 organised by Roche France (French language) |
|
| 13.00 - 14.00 |
Satellite Symposium 4 organised by Sirtex Integrating Radioembolisation into the Treatment Paradigm for Colorectal Cancer Liver Metastases |
|
| Chair: E. Cortesi, Italy | ||
| The essential elements for a successful radioembolisation practice | ||
| P. Flamen, Belgium | ||
| Clinical experience with radioembolisation for patients with mCRC failing standard-of-care chemotherapy | ||
| A. Hendlisz, Belgium | ||
| Integrating radioembolisation with early-line chemotherapy regimens for mCRC | ||
| M. Cosimelli, Italy | ||
| Panel discussion – which patients with mCRC should receive radioembolisation and at what stage? | ||
| 14.00 -15.00 | Controversy session 2 | |
| Chairs: L. Påhlman, Sweden & S. Cascinu, Italy | ||
| 11.01 | 14.00 | Intra-operative radiotherapy is a valid treatment option for rectal cancer |
| DOWNLOAD |
Pro:
V. Valentini, Italy Contra: B. Glimelius, Sweden |
|
| 11.02 | 14.30 | Synchrone resectable metastases with asymptomatic primary: Up-front chemotherapy versus resection |
| DOWNLOAD |
Chemotherapy: J.Y. Douillard, France Surgery: R. Adam, France |
|
| 15.00 - 16.15 | Multidisciplinary management 2 | |
| Chairs: C. Aschele, Italy & C.A.M. Marijnen, The Netherlands | ||
| 12.01 | 15.00 | Use of targeted therapy in combination with radiochemotherapy |
| G. Lammering, The Netherlands | ||
| 12.02 | 15.30 | Combination of targeted agents in metastatic CRC |
| DOWNLOAD | J. Tol, The Netherlands | |
| 12.03 | 16.00 | Prospective randomised trial comparing protracted IV 5FU infusion alone or with hepatic intra-arterial injection of yttrium-90 resin microspheres for patients with liver-limited metastatic colorectal cancer refractory to standard chemotherapy |
| P. Flamen, Belgium | ||
| 16.15 - 16.30 | Break | |
| 16.30 - 17.00 | Poster highlights | |
| Chairs: J.P. Gérard, France & C.J.A. Punt, The Netherlands | ||
| 17.00 - 17.50 | Highlights Sunday workshops | |
| Chairs: J.P. Gérard, France & C.J.A. Punt, The Netherlands | ||
| 17.50 - 18.00 | Closing | |